Ambrosia Biosciences
Ambrosia Biosciences is a drug discovery company developing orally delivered small-molecule therapies for obesity and other metabolic disorders. The company operates integrated U.S.-based biology and chemistry laboratories, a dedicated NMR facility, and structural biology and computational chemistry capabilities to advance programs from initial hit to IND. Their R&D emphasizes structure-based discovery for Class B GPCRs using cryo-EM, biophysical assays, AI-driven molecular design, medicinal chemistry, and rapid preclinical development.
Industries
Nr. of Employees
small (1-50)
Ambrosia Biosciences
Products
Small-molecule GLP-1 receptor agonist (once-daily) — IND-enabling
An orally delivered small-molecule GLP-1 receptor agonist program emphasizing lower effective human dosing, 24-hour target coverage, and combinability; currently in IND-enabling studies.
Small-molecule GLP-1 receptor agonist (once-weekly) — Discovery
Discovery-stage program aimed at extended half-life small-molecule GLP-1 receptor agonists to enable once-weekly dosing while maintaining differentiated performance.
GIP receptor antagonist — Discovery
Discovery-stage small-molecule program targeting GIP receptor antagonism for use in combination with GLP-1 receptor agonists to enhance efficacy while maintaining tolerability.
Amylin receptor agonist — Discovery
Discovery-stage small-molecule amylin agonist program intended for once-daily monotherapy or combination use with synergistic therapies.
GLP-1R Agonist
Developing a differentiated GLP-1 molecule demonstrating best-in-class potential with lower effective human dosing, superior 24-hour target coverage, and improved combinability.
GLP-1R Agonist QW Dosing
Extended half-life to enable once weekly dosing, while maintaining performance differentiation attributes of daily GLP-1R agonist.
Small-molecule GLP-1 receptor agonist (once-daily) — IND-enabling
An orally delivered small-molecule GLP-1 receptor agonist program emphasizing lower effective human dosing, 24-hour target coverage, and combinability; currently in IND-enabling studies.
Small-molecule GLP-1 receptor agonist (once-weekly) — Discovery
Discovery-stage program aimed at extended half-life small-molecule GLP-1 receptor agonists to enable once-weekly dosing while maintaining differentiated performance.
GIP receptor antagonist — Discovery
Discovery-stage small-molecule program targeting GIP receptor antagonism for use in combination with GLP-1 receptor agonists to enhance efficacy while maintaining tolerability.
Amylin receptor agonist — Discovery
Discovery-stage small-molecule amylin agonist program intended for once-daily monotherapy or combination use with synergistic therapies.
GLP-1R Agonist
Developing a differentiated GLP-1 molecule demonstrating best-in-class potential with lower effective human dosing, superior 24-hour target coverage, and improved combinability.
GLP-1R Agonist QW Dosing
Extended half-life to enable once weekly dosing, while maintaining performance differentiation attributes of daily GLP-1R agonist.
Expertise Areas
- Small-molecule GPCR drug discovery
- Structure-based drug design
- Medicinal chemistry
- Translational pharmacology and preclinical development
Key Technologies
- Cryo-electron microscopy (cryo-EM)
- NMR spectroscopy
- Structural biology
- Biophysical binding assays
News & Updates
Poster presentation describing nonclinical data supporting a novel oral small-molecule GLP-1 receptor agonist development candidate.
Industry article referencing efforts to develop oral small-molecule obesity treatments.
Announced an oversubscribed Series B financing round totaling $100 million.
Announced a $25 million Series A financing, including a strategic investment by a pharmaceutical company.
Recipient of the Colorado BioScience Association’s 2025 Rising Star Award.
Poster presentation describing nonclinical data supporting a novel oral small-molecule GLP-1 receptor agonist development candidate.
Industry article referencing efforts to develop oral small-molecule obesity treatments.
Announced an oversubscribed Series B financing round totaling $100 million.
Announced a $25 million Series A financing, including a strategic investment by a pharmaceutical company.
Recipient of the Colorado BioScience Association’s 2025 Rising Star Award.